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Introduction and sltmmarv/
Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease of
unknown etiology that is marked by spovial inflammation of joints, with
pain, stiffness and swelling as the main local symptoms. The chronic
slmovitis often leads to a progressive destruction of cartilage and bone.
Systemic features of inflammation may be prominent and include weight
loss, muscle weakness. fever and anaemia. The inflammatory process may
involve other organs, clinically characterized by nodules, serositis or
vasculitis. The combination of pain, stiffness, muscle weakness and joint
damage leads to physical disability, and the systemic features of the disease
add up to the ultimate handicap by impairment of the general condition.
In most patients, the course of the disease is characterized by fluctuations in
the severity of inflammatory activity. There is a large variation in the
individual course of the disease from patient to patient. The spectrum may
vary from a mild, non-destructive disease with long remissions, to a severe
course with progressive joint destruction and disability, extra-articular
manifestations, and reduced life-expectancy.
Many different quantitative measures are used to assess disease activity,
monitor the course of the disease and predict the outcome of RA. A
distinction has to be made between so called 'process variables' reflecting
the disease activity at a specific point in time, and 'outcome measures',
reflecting the result of the course of the disease over a given time period (l).
controversy still exists regarding the most appropriate measure to judge
disease activity and outcome.
'outcome' is defined as the suffering or loss of health experienced by an
individual as result of the process of a disease (2). A comprehensive measure
of outcome must therefore encompass all suffering throughout the course of
the disease. It has been generally recognized that outcome in RA has
different dimensions. Fries et al stated that an outcome measure should be
relevant to the patient and proposed five dimensions of outcome: death,
disability, discomfort (including pain, stiffness, fatigue, depression),
iahogenic effects and economic impact. Others have advocated that structural
joint damage is the predominant cause of functional impairment in RA.
Radiologically demonshable joint damage is considered to be a direct and
objective outcome measure reflecting the results of chronic joint
inflammation, including degradation of cartilage and erosion of bone.
Radiological damage meets the requirements of a real outcome measure: it is
the result of the course of the disease during the preceding period and it is
independent of the current disease activity. Other outcome measures such as
physical disability and functional tests may be largely influenced by disease
activity, particularly in the early stage of the disease. This in contrast to
advanced disease, where these measures are to a large extent determined by
ineversible joint damage (3).
'Process 
variables' measure the actual activity of the disease, and include
clinical variables, such as tender and swollen joints, and laboratory variables
such as the ery4hrocy'te sedimentation rate (ESR) and C-reactive protein
(CRP) levels. The ESR and CRP are both indicators of the 'acute phase
response', the term used to describe the complex of systemic events which
accompany inflammation. Elucidation of the role of cyokines in the
pathogenesis of inflammatory arthritis has yielded a rationale for the use of
markers of the acute phase response.
It is of importance to understand the intenelationship between process
variables and outcome, and to determire which process variables do most
adequately reflect those aspects of the disease which are representative for a
specific outcome measure.
The increasing evidence that the process of irreversible joint damage may
already starl during the first months of the disease emphasizes the need of
studies in the early stages of the disease. It is important to be able to identify
at an early stage those patients at risk of a progressive course and a poor
outcome and to have an instrument to monitor the effects of treatment aimed
at preventing or limiting joint destruction.
The aim of the study was to investigate to what extent a direct measure of
the acute phase response like CRP is a suitable process variable to monitor
the course of inflammatory activity of rheumatoid arthritis with regard to
progression of joint damage. This question was addressed by analysis of
clinical, laboratory and radiological data which were obtained during a






























rn chapÍer 1 a review is provided on the nature and the clinical relevance of
the acute phase response, in particular for the rheumatic diseases.
ln chctpters 2 and 3 the relationship between the intra-articular cy'tokine
profile and the systemic acute phase response is described. on the one hand,
(changes in) local interleukin-6 (lL-6) levels are correlated with (changes in)
the levels of other potentially deshuctive cytokines and mediators of inflam-
mation. on the other hand (changes in) local IL-6 levels appear to be related
to (changes in) the systemic levels of IL-6 and acute phase proteins as well
as other parameters of inflammatory activity.
In chaplers 1 qnd 5 the global relationship is described befween the progres-
sion of radiological damage, physical disability and the cumulative values of
CRP and jointscores. A highly significant correlation was found between the
acute phase response, number of swollen joints and the rate of progression of
radiological damage. The use in individual clinical decision making remains
limited due to a wide inter-individual variabilitv.
In chapler ó the significance of rheumatoid factor (RF) isotlpes is discussed.
The prognostic value of IgA-M and IgG-RF appears to be limited compared
to IgM-RF. Although the course of IgM-RF levels generally reflect the
course of the disease, its clinical significance as a prooess variable is mini-
mal  compared to CRP.
In chapter 7 an attempt is made to conshlct a model describing the indivi-
dual relationship befween CRP and the progression of radiological damage.
Using such a model in combination with the prognostic factors, a computer-
based "decision supporl system" can be developed, which may be applicable
in clinical practice for the individual treahnent of early RA.
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